Abstract
BackgroundDiabetes-related foot problems are bound to increase. However, medical therapies for wound care are limited; therefore, the need for development of new treatment modalities to improve wound healing in diabetic patients is essential and constitutes an emerging field of investigation.MethodsAnimals were randomly divided into 8 groups (I–VIII) (32 rats/group), all were streptozotocin (STZ)-induced diabetics except groups III and VIII were non-diabetic controls. The study comprised two experiments; the first included 3 groups. Group I injected with mononuclear cells (MNCs) derived from human umbilical cord blood (HUCB), group II a diabetic control group (PBS i.v). The second experiment included 5 groups, groups IV, V, and VI received topical HUCB-haemodialysate (HD), calves' blood HD, and solcoseryl, respectively. Group VII was the diabetic control group (topical saline). Standard circular wounds were created on the back of rats. A sample of each type of HD was analyzed using the high performance liquid chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS) system. Wound area measurement and photography were carried out every 4 days. Plasma glucose, catalase (CAT), malondialdehyde (MDA), nitric oxide (NO) and platelets count were assessed. Wound samples were excised for hydroxyproline (HP) and histopathological study.ResultsTreatment with HUCB MNCs or HUCB-HD resulted in wound contraction, increased CAT, NO, platelets count, body weights, and HP content, and decreased MDA and glucose.ConclusionSystemic administration of HUCB MNCs and topical application of the newly prepared HUCB-HD or calves' blood HD significantly accelerated the rate of diabetic wound healing and would open the possibility of their future use in regenerative medicine.
Highlights
From the chronic complications of diabetes are neuropathy and variety of connective tissue abnormalities [1]
The aim of the present study is to evaluate mononuclear cells (MNCs) derived from human umbilical cord blood (HUCB) as a cell therapy for diabetic wounds compared to untreated diabetic and normal wounds
After 4 days of treatment, HUCB MNCs resulted in a significant (p#0.001) wound closure accounting for about half of the originally opened area of the wound (49.19%) as compared to both diabetic (18.19%) and non diabetic control groups (17.4%)
Summary
From the chronic complications of diabetes are neuropathy and variety of connective tissue abnormalities [1]. To prevent or reduce surgical intervention, new therapeutic strategies are to be developed to improve diabetic wound healing. The aim of cell-based regenerative strategies is repair or enhancement of the damaged tissues’ biological function, by utilizing cells and/or bioactive molecules [5]. This can be carried out by transplantation, through local delivery or systemic infusion of autologous or allogenic cells [6]. Medical therapies for wound care are limited; the need for development of new treatment modalities to improve wound healing in diabetic patients is essential and constitutes an emerging field of investigation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
